Bruce Patterson, M.D., Founder and CEO of IncellDx™ said, “We see enormous potential to initiate the US clinical trial for HPV OncoTect®, while at the same time expanding our existing commercial efforts for Europe and Southeast Asia.”
The US High Risk (HR) HPV testing market is estimated to be $300 million dollars and growing at an annual rate of 14%. The consensus guidelines published in ACOG (2007;197 (4); 346-355) recommend HR HPV testing for cervical cancer screening in women over 21 who have abnormal PAP smears and in women over 30 years of age when used in conjunction with a PAP test.
One of the limitations of existing screening tests is lack of specificity. “Since 92% of women spontaneously clear HR HPV infections in 2 years, many women with positive test results will not proceed to cervical cancer,” said Dr. Bruce Patterson.
Since HPV OncoTect® detects and quantifies the cellular oncogenes responsible for triggering progression to cervical cancer, it has the promise of improving specificity. The unique technology behind HPV OncoTect®, has broad application for many infectious disease tests, which can be performed on the same platform.
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, HIV/AIDs, hepatitis, and organ transplant rejection.
Contact:
IncellDx, Inc. Eric Hass, 1-650-777-7630 www.incelldx.com
